Outlook Therapeutics, Inc. (OTLK): Operating Income
-$67.06M
Year ended 2025-09-30
-$55.64M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$67.06M | n/m | 2025-12-19, From 2024-10-01 |
| 2024-09-30 | -$71.70M | n/m | 2025-12-19, From 2023-10-01 |
| 2023-09-30 | -$53.13M | n/m | 2024-12-27, From 2022-10-01 |
| 2022-09-30 | -$63.07M | n/m | 2023-12-22, From 2021-10-01 |
| 2021-09-30 | -$51.73M | n/m | 2022-12-29, From 2020-10-01 |
| 2020-09-30 | -$36.84M | n/m | 2021-12-23, From 2019-10-01 |
| 2019-09-30 | -$36.30M | n/m | 2020-12-23, From 2018-10-01 |
| 2018-09-30 | -$29.64M | n/m | 2019-12-19, From 2017-10-01 |
| 2017-09-30 | -$35.88M | n/m | 2018-12-18, From 2016-10-01 |
| 2016-09-30 | -$51.35M | n/m | 2017-12-29, From 2015-10-01 |
| 2015-09-30 | -$46.56M | n/a | 2016-12-29, From 2014-10-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$67.06M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | -$7.54M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$135.03M | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$24.94M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | -$108.14M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | -$87.98M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$165.01M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$48.45M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | -$7.19M | n/m |
Compare OTLK, SCNI, INBX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗